DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation

Information source: Federal University of São Paulo
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infection and Inflammation After Refractive Surgery (Lasik).

Intervention: 0.3% gatifloxacin and 1.0% prednisolone acetate association (Drug); isolated 0.3% gatifloxacin and 1.0% prednisolone acetate (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Federal University of São Paulo

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan


The purpose of the study is to evaluate the safety and tolerance of the 0. 3% gatifloxacin and 1. 0% prednisolone acetate association in eye drops in the prevention of infection and inflammation after refractive surgery (Lasik) and also demonstrate the non-inferiority of the efficacy of this association compared to the administration of 0. 3% gatifloxacin and 1. 0% prednisolone acetate as isolated eye drops formulations. The study treatment is randomized, double-masked, with 2 parallel arms. Each patient's participation lasts 29 days, with 15 days of study treatment administration after the ocular surgery is performed. Candidates for the study are patients with indication for ocular refractive surgery (Lasik) for correction of visual acuity.

Clinical Details

Official title: Double-Masked, Randomized, Parallel Group Study for Evaluation of Non-Inferiority of 0.3%Gatifloxacin/1.0% Prednisolone Association Compared With Their Isolated Administration in the Prevention of Ocular Infection/Inflammation After LASIK Surgery

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Percentage of eyes with absence of signs/symptoms of ocular infection/inflammation after surgery.


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Patient is indicated to have an ocular refractive surgery performed (myopia,

astigmatism, hypermetropy) by the Lasik method.

- Patient presents a normal eye fundus.

- Patient has intraocular pressure (IOP) ≤ 20 mmHg.

Exclusion Criteria:

- Surgery and/or previous ocular pathology (presence of scar/change in the cornea,

glaucoma, retinopathies, etc.).

- Patient has diabetes or is immunodepressed.

- Any systemic infection during the study.

- Signs and/or symptoms of ocular inflammation/infection (bacterial, viral, fungal,

caused by Chlamydia, by Mycobacterium, Acanthamoeba or of allergic etiology).

- Have used any systemic or topical antibiotics for ocular infection in the previous 14


- Patient has known hypersensitivity to any of the components of the formulations used

in the study.

Locations and Contacts

Federal University of Sao Paulo - Dept of Ophthalmology, Sao Paulo, SP 04023-062, Brazil
Additional Information

Starting date: January 2009
Last updated: October 14, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017